Navigation Links
AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Date:5/6/2011

REDWOOD CITY, Calif., May 6, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at The Tenth Annual JMP Securities Research Conference at the San Francisco Ritz Carlton. The presentation is scheduled for Monday, May 9, 2011 at 12:30p.m. PT.  

The presentation will be webcast live and can be accessed through http://wsw.com/webcast/jmp13/acrx/.  For those who are not available to listen to the live broadcast, the presentation will be archived and available through http://www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab(TM) PCA System, which has completed Phase 2 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA) which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
2. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
3. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
4. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
7. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
8. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
9. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
10. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
11. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... known U.S. mesh product liability claims and that it ... U.S. claims at reasonable values. Under the agreements, Endo ... of 2017 and continuing through the fourth quarter of ... the Company intends to increase its mesh product liability ...
(Date:8/3/2017)... 3, 2017  Opioid addiction and other drugs of ... costs and threatening outcomes, were problems taken on directly ... industry that support them, met this week. This according ... that drugs of abuse, procalcitonin and acute kidney injury ... organization,s 69th meeting in San Diego, CA. ...
(Date:8/2/2017)... -- Life Flight Network and PeaceHealth Oregon Network announced they renewed ... operational efficiency for patients at hospitals in Eugene ... Grove , and Florence, Oregon , ... Network work collaboratively to move patients who require the highest ... sensitive emergency exists. ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon running has surged ... country. , Outdoor running increases exposure to ultraviolet radiation, a carcinogen that promotes ... melanoma, and only half may be adequately protecting themselves with proper clothing and ...
(Date:8/21/2017)... ... August 21, 2017 , ... The experts have spoken. Prolonged ... supposed to get things done in a healthy way these days? FlexiSpot, one of ... crowdfunding campaign on August 28 to introduce Deskcise Pro™– the world’s first sit-stand-cycle desk ...
(Date:8/21/2017)... ... ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse Executive at ... Trustees for a three-year term beginning January 1, 2018. , The AHA ... committed to the improvement of health in their communities. Founded in 1898, the AHA ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar partnership commitment ... post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over the next year. ...
(Date:8/20/2017)... ... August 20, 2017 , ... A total solar eclipse will occur across the U.S. ... the moon moves between the sun and Earth. This rare event will be magnificent to ... help keep you safe on the road during the total eclipse of the sun. , ...
Breaking Medicine News(10 mins):